Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease

Experimental and Therapeutic Medicine

Volumn 5, Issue 5, 2013, Pages 1451-1455

  Li, Shuai Bing ^a   Yang, Fan ^a   Jing, Li ^a   Ma, Juan ^a   Jia, Ya Dan ^a   Dong, Shao Ying ^a   Zheng, Wei Feng ^a   Zhao, Luo Sha ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Atherosclerosis; Biomarker; Lipoprotein associated phospholipase A2; Peripheral arterial disease; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; C REACTIVE PROTEIN; FIBRINOGEN; HOMOCYSTEINE; PHOSPHOLIPASE A2;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE;

EID: 84876536147     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1005     Document Type: Article

References (29)

1. Murabito JM, Evans JC, Larson MG, Nieto K, Levy D and Wilson PW: The anklebrachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med 163: 1939-1942, 2003.
2. Hiatt WR: Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344: 1608-1621, 2001.
3. Belch JJ, Topol EJ and Agnelli G, et al: Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 163: 884-892, 2003.
4. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126, 1999.
5. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictorsof peripheral arterial disease. JAMA 285: 2481-85, 2001.
6. McDermott MM, Green D and Greenland P, et al: Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 92: 194-199. 2003.
7. Kolodgie FD, Burke AP and Skorija KS, et al: Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 26: 2523-2529, 2006.
8. Mannheim D, Herrmann J and Versari D, et al: Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 39: 1448-1455, 2008.
9. Rader DJ: Inflammatory markers of coronary risk. N Engl J Med 343: 1179-1182, 2000.
10. Karasawa K, Harada A, Satoh N, Inoue K and Setaka M: Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 42: 93-114, 2003.
11. Tsimikas S, Tsironis LD and Tselepis AD: New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 27: 2094-2099, 2007.
12. McConnell JP and Hoefner DM: Lipoprotein-associated phospholipase A2. Clin Lab Med 26: 679-697, 2006.
13. Sudhir K: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab 90: 3100-3105, 2005.
14. Quigley FG, Faris IB and Duncan HJ: A comparison of Doppler ankle pressures and skin perfusion pressure in subjects with and without diabetes. Clin Physiol 11: 21-25, 1991.
15. Lijmer JG, Hunink MG, van den Dungen JJ, Loonstra J and Smit AJ: ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol 22: 391-398, 1996.
16. Carter SA: The role of pressure measurements in vascular disease. In: Non-Invasive Diagnostic Techniques in Vascular Disease. Bernstein EF (ed). Mosby, Missouri, pp513-544, 1985.
17. Yao IST: Pressure measurement in the extremity. In: Vascular Diagnosis. Bernstein EF (ed.) 4th edition. Mosby, Missouri, pp169-175, 1993.
18. Fowkes FG: The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol 17: 248-154, 1988.
19. Hirsch AT, Haskal ZJ and Hertzer NR, et al: ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric and abdominal aortic). Circulation 113: e463-e654, 2006.
20. The Lp-PLA2 Studies Collaboration: Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375: 1536-1544, 2010.
21. Gong HP, Du YM, Zhong LN, Dong ZQ, Wang X, Mao YJ and Lu QH: Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis. Lipids Health Dis 10: 13, 2011.
22. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G and Sharrett AR: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 109: 837-842, 2004.
23. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG and Berger PB: Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease and major adverse events at follow-up. Eur Heart J 26: 137-144, 2005.
24. Stafforini DM, Tjoelker LW and McCormick SP, et al: Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 274: 7018-7024, 1999.
25. Alberti KG, Zimmet P and Shaw J, et al: The metabolic syndrome-a new worldwide definition. Lancet 366: 1059-1062, 2005.
26. Kume N and Gimbrone MA Jr: Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 93: 907-911, 1994.
27. Tselepis AD and John Chapman M: Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 3: 57-68, 2002.
28. Páramo JA, Beloqui O, Roncal C, Benito A and Orbe J: Validation of plasma fibrinogen as a marker of carotid atherosclerosis in subjects free of clinical cardiovascular disease. Haematologica 89: 1226-1231, 2004.
29. Nasir K, Guallar E, Navas-Acien A, Criqui MH and Lima JA: Relationship of monocyte count and peripheral arterial disease: results from the National Health and Nutrition Examination Survey 1999-2002. Arterioscler Thromb Vasc Biol 25: 1966-1971, 2005.